Last reviewed · How we verify

low-dose atorvastatin

Wakayama Medical University · FDA-approved active Small molecule Under review

low-dose atorvastatin is a HMG-CoA reductase inhibitor (statin) Small molecule drug developed by Wakayama Medical University. It is currently FDA-approved for Hypercholesterolemia, Cardiovascular disease prevention, Dyslipidemia. Also known as: Lipitor5.

Low-dose atorvastatin inhibits HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels.

Low-dose atorvastatin has been studied in clinical trials for conditions such as hyperlipidemias, contrast-induced acute kidney injury, cardiovascular diseases, coronary artery disease, and HMG-CoA Reductase Inhibitor toxicity. Atorvastatin, a medication that inhibits HMG-CoA reductase, has been evaluated in a phase 1 study (NCT06239714) for its effects on elevated low-density lipoprotein cholesterol (LDL-C).

At a glance

Generic namelow-dose atorvastatin
Also known asLipitor5
SponsorWakayama Medical University
Drug classHMG-CoA reductase inhibitor (statin)
TargetHMG-CoA reductase
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Atorvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. By reducing hepatic cholesterol production, it lowers circulating LDL cholesterol and triglycerides while modestly increasing HDL cholesterol. Low-dose formulations maintain efficacy while potentially reducing adverse effects associated with higher doses.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about low-dose atorvastatin

What is low-dose atorvastatin?

low-dose atorvastatin is a HMG-CoA reductase inhibitor (statin) drug developed by Wakayama Medical University, indicated for Hypercholesterolemia, Cardiovascular disease prevention, Dyslipidemia.

How does low-dose atorvastatin work?

Low-dose atorvastatin inhibits HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels.

What is low-dose atorvastatin used for?

low-dose atorvastatin is indicated for Hypercholesterolemia, Cardiovascular disease prevention, Dyslipidemia.

Who makes low-dose atorvastatin?

low-dose atorvastatin is developed and marketed by Wakayama Medical University (see full Wakayama Medical University pipeline at /company/wakayama-medical-university).

Is low-dose atorvastatin also known as anything else?

low-dose atorvastatin is also known as Lipitor5.

What drug class is low-dose atorvastatin in?

low-dose atorvastatin belongs to the HMG-CoA reductase inhibitor (statin) class. See all HMG-CoA reductase inhibitor (statin) drugs at /class/hmg-coa-reductase-inhibitor-statin.

What development phase is low-dose atorvastatin in?

low-dose atorvastatin is FDA-approved (marketed).

What are the side effects of low-dose atorvastatin?

Common side effects of low-dose atorvastatin include Muscle pain or myalgia, Elevated liver enzymes, Headache, Rhabdomyolysis.

What does low-dose atorvastatin target?

low-dose atorvastatin targets HMG-CoA reductase and is a HMG-CoA reductase inhibitor (statin).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing